4
Changes in Ownership
CytomX Therapeutics, Inc. Filed Acc 0001140361-17-012870
Chief Financial Officer sold 21,517 shares at an average $19.81 ($426,340)
- Chief Financial Officer acquired 21,517 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Goeltz II Robert C. · Chief Financial Officer
Table I: Non-derivative
3 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2017-03-20 | Exercise or conversion : show line 1 in the form | +21,517 | $4.47 | $96,241 | 31,306 | D |
| 2017-03-20 | Sale : show line 2 in the form | −10,000 | $19.60 | $196,000 | 21,306 | D |
| 2017-03-20 | Sale : show line 3 in the form | −11,517 | $20.00 | $230,340 | 9,789 | D |
| Open-market sales · 21,517 sh · avg $19.81 · $426,340 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2017-03-20 | Exercise or conversion : show line 4 in the form Stock Option (Right to Buy) | −21,517 | 217,658 | D |
Loading xslF345X03/doc1.xml…